St. Jude Medical Announces Australian Market Launch for First-of-Its-Kind Neurostimulation Lead Delivery System for Chronic Pain
May 23 2011 - 1:00AM
Business Wire
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the Australian market launch of the
Epiducer™ lead delivery system for neurostimulation therapy for the
management of chronic pain. Showcased at the International
Neuromodulation Society 10th World Congress in London, England,
this unique system gives physicians the ability to place multiple
neurostimulation leads through a single entry point, including
proprietary S-Series™ steerable paddle leads, which are designed
for minimally invasive placement.
The Epiducer(TM) lead delivery system
enables the placement of multiple neurostimulation percutaneous
leads and S-Series(TM) paddle leads through a single entry point.
Neurostimulation leads are utilized in spinal cord stimulation
(SCS) therapy for the management of chronic pain. Image provided by
St. Jude Medical, Inc.
This first-of-its-kind system is designed to lessen procedural
complexities and improve efficiency in the placement of
neurostimulation leads utilized in spinal cord stimulation (SCS)
therapy for the management of chronic pain. Prior to the Epiducer
system, the placement of multiple percutaneous neurostimulation
leads required several small incisions. In addition, a paddle lead
implant required a laminotomy, a more invasive surgical procedure
that typically requires removal of part of the vertebral bone.
Physicians often utilize more than one lead or combine different
types of leads such as percutaneous and surgical paddle leads to
manage complex pain such as low back pain.
“As pain physicians, if we can perform a simpler, less invasive
procedure while delivering the same degree of effective care, the
patient benefits,” said Peter Courtney, MBBS,
FIPP of the Melbourne Pain Group in Melbourne, Australia. “The
Epiducer system has allowed me to use lead combinations for my
patients and capture pain patterns that would have required a much
more complicated procedure.”
The Epiducer system is the latest addition to the St. Jude
Medical product portfolio which includes industry firsts such as
the world’s smallest neurostimulator for chronic pain -- the Eon
Mini™ spinal cord stimulator.
“The Epiducer lead delivery system provides physicians more
flexibility in the placement of neurostimulation leads for the
management of chronic pain,” said Chris Chavez, president of the
St. Jude Medical Neuromodulation Division. “Providing physicians
with clinically relevant new products like the Epiducer system
enables them to have more control and less procedural risks when
providing patients with this life-changing therapy.”
Neurostimulation (also called spinal cord stimulation) is used
for managing chronic pain of the trunk and limbs and pain from back
surgeries that have failed. Mild electrical pulses are carried from
the neurostimulator to a lead or leads that are placed in the
epidural space near the spine to interrupt or mask the transmission
of pain signals to the brain. Electrodes on the lead can be
programmed to meet individual patient’s needs. More information can
be obtained about neurostimulation therapy at
www.PowerOverYourPain.com.
Three decades of leading edge neurostimulation
technology
For more than 30 years, the St. Jude Medical Neuromodulation
Division has developed new technologies to treat chronic pain and
other neurological disorders. Today more than 75,000 patients in 40
countries have been implanted with St. Jude Medical
neurostimulation systems.
Focused on research, St. Jude Medical is developing new
technologies to address a growing list of neurological disorders.
Clinical studies are currently underway for Parkinson’s disease,
essential tremor, migraine headaches, major depressive disorder,
and others.
Chronic pain is a largely under-treated and misunderstood
condition that affects millions of patients worldwide. The World
Health Organization, in conjunction with the International
Association for the Study of Pain (IASP), reports that as many as
one in five people suffers from moderate to severe chronic
pain.
About St. Jude Medical
St. Jude Medical develops medical technology and services that
focus on putting more control into the hands of those who treat
cardiac, neurological and chronic pain patients worldwide. The
company is dedicated to advancing the practice of medicine by
reducing risk wherever possible and contributing to successful
outcomes for every patient. St. Jude Medical is headquartered in
St. Paul, Minn. and has four major focus areas that include:
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal
quarter ended April 2, 2011. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6733108&lang=en
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024